Liquidia Corporation (NASDAQ:LQDA) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET

Company Participants

Jason Adair – Senior Vice President-Corporate Development and Strategy

Roger Jeffs – Chief Executive Officer

Rusty Schundler – General Counsel

Mike Kaseta – Chief Financial Officer

Rajeev Saggar – Chief Medical Officer

Conference Call Participants

Greg Harrison – Bank of America

Chris Howerton – Jefferies

Julian Harris – BTIG

Matt Kaplan – Ladenburg

Serge Belanger – Needham & Company

Operator

Good morning, and welcome, everyone, to the Liquidia Corporation Third Quarter 2022 Financial Results and Corporate Update Conference Call. My name is Abby, and I will be your conference operator today. Currently, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session, instructions will be provided at that time for you to queue up for questions. [Operator Instructions] I would like to remind everyone that this conference call is being recorded.

I will now hand the call over to Jason Adair, Senior Vice President, Corporate Development and Strategy.

Jason Adair

Thank you, Abby. It's my pleasure to welcome everyone to Liquidia's third quarter 2022 financial results and corporate update conference call. Joining the call today are Chief Executive Officer, Roger Jeffs; Chief Financial Officer, Mike Kaseta; General Counsel, Rusty Schundler; and other members of the Liquidia management team.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause actual results or performance to be materially different from any future results or performance expressed or implied on the call.

For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website.

I'd now like to turn the call over to Roger for our prepared remarks, after which we will open the call up for your questions. Roger?

Roger Jeffs

Thank you, Jason. Good morning, everyone, and thank you for joining us. I firmly believe we will look back at the third quarter as a seminal point in our mission to bring YUTREPIA to patients. Notably, and as Rusty will expand upon shortly, we achieved outcomes in our legal proceedings that have simply affirmed on appeal will allow us to launch YUTREPIA as all of the asserted patent claims have been found in at least one proceeding to be invalid or not infringed.